@article{e5f432578e084d00a1a1bdaa5c82d9c8,
title = "Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression",
abstract = "Objective: To examine the effect of high baseline anxiety on response to ketamine versus midazolam (active placebo) in treatment-resistant depression (TRD). Methods: In a multisite, double-blind, placebo-controlled trial, 99 subjects with TRD were randomized to one of five arms: a single dose of intravenous ketamine 0.1, 0.2, 0.5, 1.0 mg/kg, or midazolam 0.045 mg/kg. The primary outcome measure was change in the six-item Hamilton Rating Scale for Depression (HAMD6). A linear mixed effects model was used to examine the effect of anxious depression baseline status (defined by a Hamilton Depression Rating Scale Anxiety-Somatization score ≥7) on response to ketamine versus midazolam at 1 and 3 days postinfusion. Results: N = 45 subjects had anxious TRD, compared to N = 54 subjects without high anxiety at baseline. No statistically significant interaction effect was found between treatment group assignment (combined ketamine treatment groups versus midazolam) and anxious/nonanxious status on HAMD6 score at either days 1 or 3 postinfusion (Day 1: F(1, 84) = 0.02, P = 0.88; Day 3: F(1, 82) = 0.12, P = 0.73). Conclusion: In contrast with what is observed with traditional antidepressants, response to ketamine may be similar in both anxious and nonanxious TRD subjects. These pilot results suggest the potential utility of ketamine in the treatment of anxious TRD.",
keywords = "active placebo, anxious depression, ketamine, major depressive disorder, midazolam, treatment-resistant depression",
author = "Salloum, {Naji C.} and Maurizio Fava and Freeman, {Marlene P.} and Martina Flynn and Bettina Hoeppner and Hock, {Rebecca S.} and Cristina Cusin and Iosifescu, {Dan V.} and Trivedi, {Madhukar H} and Gerard Sanacora and Mathew, {Sanjay J.} and Charles Debattista and Ionescu, {Dawn F.} and Papakostas, {George I.}",
note = "Funding Information: Cristina Cusin: Research: from NIMH (R01MH102279); consulting fees: from Janssen Pharmaceuticals, Takeda, Boehringer, Lundbeck. She has also participated in research funded by Janssen, Medtronic, Otsuka, Takeda. Funding Information: This project was funded by the National Institute of Mental Health (NIMH) under Contract Rapidly Acting Treatments for Treatment-Resistant Depression (RAPID) number: HHSN271201100006I, to the Massachusetts General Hospital (Maurizio Fava, MD and George Papakostas, co-principal investigators). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. We would like to thank Drs. Mi Hillefors, Steven Zalcman, Adam Haim, and Galia Siegel from NIMH, for their support, which was absolutely critical to both the planning and the implementation of the study. Funding Information: Dan V. Iosifescu: Over the last 12 months Dr. Iosifescu reports consulting fees from Axsome, Alkermes, Centers of Psychiatric Excellence, Jazz, and Lundbeck, and research grants from LiteCure and Neosync. Funding Information: Charles Debattista: Dr. DeBattista has received grant support from Janssen, Neuronetics, St. Jude, and Biolite. He has served on the Advisory Board of Alkermes. Publisher Copyright: {\textcopyright} 2018 Wiley Periodicals, Inc.",
year = "2019",
month = mar,
doi = "10.1002/da.22875",
language = "English (US)",
volume = "36",
pages = "235--243",
journal = "Depression and anxiety",
issn = "1091-4269",
publisher = "Wiley-Blackwell",
number = "3",
}